ArticleThe Journal of clinical investigation2001
A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function.
Article in The Journal of clinical investigation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 135 citations in OpenAlex.
- Extracellular derivatives for bone metabolism.Journal of advanced research · 2024Review
- Differential effects of clopidogrel and/or aspirin on the healing of tooth extraction wound bone tissue.Frontiers in physiology · 2024Article
- A Zeb1/MtCK1 metabolic axis controls osteoclast activation and skeletal remodeling.The EMBO journal · 2023Article
- Plasma Membrane Receptors Involved in the Binding and Response of Osteoclasts to Noncellular Components of the Bone.International journal of molecular sciences · 2021Review
- Itgb3-integrin-deficient mice may not be a sufficient model for patients with Glanzmann thrombasthenia.Molecular medicine reports · 2021Article
- The M-CSF receptor in osteoclasts and beyond.Experimental & molecular medicine · 2020Review
- The Genetic Architecture of High Bone Mass.Frontiers in endocrinology · 2020Review
- Modulation of αActa histochemica et cytochemica · 2019Article
- L-plastin phosphorylation regulates the early phase of sealing ring formation by actin bundling process in mouse osteoclasts.Experimental cell research · 2018Article
- Phenotype and Function of Myeloid-Derived Suppressor Cells Induced by Porphyromonas gingivalis Infection.Infection and immunity · 2017Article
- Binding of CIB1 to the αIIb tail of αIIbβ3 is required for FAK recruitment and activation in platelets.PloS one · 2017Article
- The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.The Journal of biological chemistry · 2015Article
- Ubiquitin E3 Ligase LNX2 is Critical for Osteoclastogenesis In Vitro by Regulating M-CSF/RANKL Signaling and Notch2.Calcified tissue international · 2015Article
- [Effect of zoledronate on the osteoclast adhesion and gene expression of integrin α(v) and β3].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2014Article
- RBP-J imposes a requirement for ITAM-mediated costimulation of osteoclastogenesis.The Journal of clinical investigation · 2014Article
- The integrin adhesome: from genes and proteins to human disease.Nature reviews. Molecular cell biology · 2014Review
- Osteoclasts: New Insights.Bone research · 2013Review
- Talin1 and Rap1 are critical for osteoclast function.Molecular and cellular biology · 2013Article
- The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.The Journal of clinical investigation · 2012Article
- c-Src links a RANK/αvβ3 integrin complex to the osteoclast cytoskeleton.Molecular and cellular biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Osteoclastic bone resorption requires cell-matrix contact, an event mediated by the alpha v beta 3 integrin. The structural components of the integrin that mediate osteoclast function are, however, not in hand. To address this issue, we generated mice lacking the beta 3 integrin gene, which have dysfunctional osteoclasts. Here, we show the full rescue of beta 3(-/-) osteoclast function following expression of a full-length beta 3 integrin. In contrast, truncated beta 3, lacking a cytoplasmic domain (h beta 3c), is completely ineffective in restoring function to beta 3(-/-) osteoclasts. To identify the components of the beta 3 cytoplasmic domain regulating osteoclast function, we generated six point mutants known, in other circumstances, to mediate beta integrin signaling. Of the six, only the S(752)P substitution, which also characterizes a form of the human bleeding disorder Glanzmann's thrombasthenia, fails to rescue beta 3(-/-) osteoclasts or restore ligand-activated signaling in the form of c-src activation. Interestingly, the double mutation Y(747)F/Y(759)F, which disrupts platelet function, does not affect the osteoclast. Thus similarities and distinctions exist in the mechanisms by which the beta 3 integrin regulates platelets and osteoclasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.